We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
AstraZeneca Licenses Labguru Research and Lab Management Software
Product News

AstraZeneca Licenses Labguru Research and Lab Management Software

AstraZeneca Licenses Labguru Research and Lab Management Software
Product News

AstraZeneca Licenses Labguru Research and Lab Management Software


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "AstraZeneca Licenses Labguru Research and Lab Management Software"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioData, producer of Labguru has announced that the Innovative Medicines unit of global pharmaceutical business, AstraZeneca, has adopted the Labguru platform for the global management of biological reagents used in pre-clinical research.

Scientists will use the Labguru platform across multiple AstraZeneca sites in North America and Europe, replacing and consolidating several legacy systems spanning several scientific disciplines. Its modular web-based system offers an easy means of tracking projects, protocols, biological collections and materials, as well as streamlining collaboration between members of the lab and between institutions.

Lorenz Mayr, VP of Reagents and Assay Development at AstraZeneca explained: “We conducted a comprehensive evaluation and found Labguru to be the most suitable solution for the management of our global preclinical biological reagents. BioData’s experience with supporting academic groups, together with the cloud-based Labguru installation, will allow AstraZeneca scientists greater opportunities to share our biological research reagents with future external partners, to support new drug discovery projects for which there is currently an unmet medical need.”

Louis Culot, Chief Executive Officer of BioDatasaid: “AstraZeneca selected Labguru after a rigorous assessment of their needs and available solutions. Our approach comprising an integrated scientific research platform that currently enables multi-site academic collaboration, is resulting in measurable improvements in laboratory management, scientific reproducibility, and transparency. We look forward to supporting AstraZeneca's vision of delivering life-changing medicines to patients.”

A Digital Science portfolio company, BioData’s services benefit individual researchers at the bench, and also enhance collaboration and knowledge management across research teams and institutions. Labguru’s order management, equipment sharing, and storage mapping features reduce costs and streamline administrative tasks.

Advertisement